Brief: Ipsen's Iqirvo Demonstrates Statistically Significant Improvement In ALP Normalisation In Patients With PCB

Ipsen SA

13/07/2026 06:06

July 13 (Reuters) - Ipsen SA IPN.PA:
IQIRVO® DEMONSTRATES A STATISTICALLY SIGNIFICANT IMPROVEMENT IN ALP NORMALISATION IN PATIENTS WITH PCB, ACCORDING TO THE RESULTS OF THE PHASE IIIB ELSPIRE STUDY
PRIMARY ENDPOINT OF ALP NORMALIZATION WAS ACHIEVED IN 85% OF PATIENTS TREATED WITH IQIRVO® (ELAFIBRANOR) VERSUS 23% ON PLACEBO
IPSEN PLANS TO PRESENT THESE DATA AT AN UPCOMING MEDICAL MEETING AND SUBMIT TO REGULATORY AUTHORITIES
Source text: Full press release
Further company coverage: IPN.PA

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))